Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Blinks But Is $93 Enough For Genentech Shareholders?

This article was originally published in The Pink Sheet Daily

Executive Summary

The $6.50 per share increase in Roche’s offer also includes an extension of the tender deadline to March 20.

You may also be interested in...



Roche Wins Genentech, But Will Biotech Employees Remain?

After eight months of haggling, Roche finally struck a deal to pay $95 a share for Genentech, an iconic biotech in which the drug maker already owns a 56 percent stake

Roche Wins Genentech, But Will Biotech Employees Remain?

After eight months of haggling, Roche finally struck a deal to pay $95 a share for Genentech, an iconic biotech in which the drug maker already owns a 56 percent stake

Roche Wins Genentech, But Will Biotech Employees Remain?

With a sweetened bid, the Swiss pharma gains the blessing of Genentech’s special committee, but whether the innovator’s valuable staffers sanction the union is an open question.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134882

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel